Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

Helse Stavanger HF

Status: Enrolling

Conditions: Central Serous Chorioretinopathy

Treatments: Drug: Verteporfin

Study type: Observational

Funder types: Other

Identifiers

NCT05589974

REK485079

Details and patient eligibility

About

Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.

Full description

Acute CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics are related to the eventual resolution of subretinal fluid. Such relation can shed light on pathophysiological disease mechanisms and constitute a biomarker for disease activity.

Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:-

• Able to sign informed consent

• Possible to obtain fundus imaging

• Acute CSC ˂4 months of duration in one eye, defined as:

  1. Subfoveal presence of SRF on OCT
  2. Present attack is 1st -3rd attack of CSC

  b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT

• Chronic CSC ≥4 months of duration in one eye, defined as:

  1. Subfoveal presence of SRF on OCT
  2. Subjective visual loss/symptoms
  3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT
  4. Patient history and examination consistent with chronic CSC

Exclusion Criteria:

• History of retinal disease other than CSC (e.g. retinal detachment)
• Contraindications for FA, ICGA or PDT (only for chronic CSC)

Trial design

50 participants in 2 patient groups

Acute

Description:

Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.

Chronic

Description:

Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.

Treatment:

Drug: Verteporfin